Centene
Valuation each multiple against its own 5-year range
Vs. peers Healthcare Plans
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Centene (CNC) | 31.58B | 21.92 | 1.42 | 0.00% |
| UnitedHealth (UNH) | 304.51B | 19.40 | 3.10 | 2.67% |
| CVS Health (CVS) | 103.43B | 9.39 | 1.28 | 3.29% |
| Elevance Health (ELV) | 85.23B | 16.75 | 1.91 | 1.74% |
| Cigna Group (CI) | 71.38B | 11.94 | 1.65 | 2.28% |
| Humana (HUM) | 46.84B | 38.05 | 2.49 | 0.68% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 17.6% below Morningstar's fair value estimate.
Analyst note
On Nov. 13, the Centers for Medicare and Medicaid Services delayed the implementation of new Medicaid work requirements by six months. Then, on Nov. 16, CMS highlighted overpayment estimates in Medicare Advantage. Covered MCO shares fell 8% on average from the close on Nov. 13 through Nov. 18.
Why it matters: The first new managed care organization policy looks like a mild positive for Medicaid-focused insurers like Centene, Elevance, and Molina. However, the second policy looks negative for Medicare Advantage-focused insurers like UnitedHealth, Humana, and CVS. Based on the slight delay in implementing work requirements in Medicaid, we do not expect to materially change any fair values on our list on that news. The Medicare Advantage story is a bit more complicated, as CMS merely announced the total overpayment estimates in recent years, not how much it intends to claw back from each Medicare Advantage insurer. Since we have already included potential clawbacks and lower ongoing margins in MA in our MCO models since May 2025, we do not intend to change our cash flow estimates at this time.
The bottom line: While we are not changing any fair value estimates currently on the managed care companies that we cover, we recognize the elevated uncertainty that these companies face due to ongoing regulatory scrutiny, like the new potential MA clawbacks on deck. For perspective, our Morningstar Uncertainty Ratings on the MCOs are currently about one notch higher than typical due to potentially negative regulations, like current scrutiny on MA risk assessments. However, since May 2025, we have included substantial cash outflows in our models for each insurer with Medicare Advantage exposure related to potential clawbacks being teed up by this announcement. At that time, we also lowered our long-term margin target in MA due to the potential for lower risk-related payments.
BLANK PAGEHowever, we recognize that the assessed fines may wind up being higher than we currently estimate. For example, based on the estimated overpayments and market share data in MA, we estimate that UnitedHealth may be subject to a roughly $35 billion clawback from years 2018-26 versus the $20 billion we currently estimate in our model. However, that potentially higher clawback would not meet the 5% materiality threshold to change our fair value estimate on UnitedHealth, assuming no other potential changes to our expectations.
Using a similar approach, the valuations of Elevance, Centene, Cigna, and Molina would not be materially affected by such a clawback.
More negatively, Humana's fair value estimate could decline more than 20% in such a scenario, which would put its fair value estimate more in line with recent share prices. Also, depending on its financing needs and timing related to this potential outflow, the company may run into debt covenant challenges. So its shares could be especially volatile, given its exposure to this concern.
Also, CVS recently announced a settlement with CMS on this topic for most of the timeframe highlighted. We assume that a recent settlement with CMS eliminated the vast majority of its liability. If we are incorrect in that assumption, though, CVS' fair value estimate could face up to a high-single-digit percentage cut to its fair value estimate.
Our assumption that fines will be roughly assessed by market share in Medicare Advantage in the above scenario may be incorrect, too, as there may be bad actors in risk assessments in MA. For example, an October 2024 Office of Inspector General report suggested UnitedHealth accounted for roughly half of all inappropriate risk assessments in the studied group, or roughly double its MA market share. If that is correct, UnitedHealth's financial liability could roughly triple from what is in our current model (and cause a mid-single-digit percentage decline in its fair value) from what is in our current model. In that scenario, other MA insurers (the less egregious actors) may face lower financial liabilities than we currently estimate.
For more details on the managed care organizations, including the industry's growth prospects, moat ratings, moat sources, and regulatory concerns like potential MA risk assessment-related clawbacks, please see our September 2026 report, "Industry Landscape: Managed Care Organizations."
Fair value
To recognize higher near-term expectations and cash flows generated since our last valuation update, we are increasing our fair value estimate on Centene to $75 per share from $70 previously.
Including pressures through 2027, we expect 4% revenue growth compounded annually through 2030, and our fair value estimate depends on Centene's operating margins returning to about 2% by 2030, up from roughly breakeven in 2025. Currently, medical utilization appears elevated in most of its end markets, including the important individual plans and Medicaid population, which has pushed margins down substantially. Also, with Congress recently passing a budget reconciliation bill in 2025 that will cut into the Medicaid population (2027) and allow subsidies in the individual plan market to expire (2026), additional headwinds to revenue and profits in those markets may constrain margins in the near term. However, we still think margins should rise materially over time, as rates and utilization come more into balance, creating significant upside potential for Centene's profits if it can navigate its near-term challenges.
Economic moat
In April 2025, we downgraded our moat rating to none from narrow because of ongoing pressures in Medicaid related to mismatched rates and utilization and also regulatory challenges that could cut into Centene's economic profitability in its key end markets in the near term—Medicaid and the individual exchanges. Profits may remain under pressure at least through 2027, as medical utilization remains elevated in its individual and Medicaid end markets and as regulatory pressures mount on the individual exchanges (2026) and Medicaid (2027) in terms of both enrollment and potential mix pressures.
Medicaid Market Under Pressure Due to Mismatched Rates/Utilization and Regulatory Scrutiny
Centene is the leading provider of Medicaid’s managed care plans, which serve low-income individuals and people with disabilities. In a normalized environment, we expect that just under half of Centene’s profits will be generated from its Medicaid business, making that business the primary determinant of its moat rating and sources. Historically, we thought Centene benefited from cost advantages and customer switching costs in this unique medical insurance market, which garners very low margins in the best environment. Given the pressures that this market is under now with mismatched rates and utilization combined with regulatory scrutiny under Republican leadership, we view its path to durable economic profit generation in this end market as too uncertain to meet the "more likely than not" test that we require when assigning economic moat ratings, despite its significant scale, efficient operations, and effective programs that help it offer plans at lower rates than other private health insurers and contributes to its market-leading position in the Medicaid managed care business.
We also believe the Medicaid market has the potential to create switching costs through contractual obligations and entrenched relationships, and the strength of those switching costs makes the Medicaid business relatively unique in the health insurance industry. For example, employers typically only contract with a medical insurer for one year. In contrast, while contract terms vary by state, initial Medicaid contract lengths with managed care companies typically last three to five years. Additional renewal periods can lengthen those initial contract periods by several years as well, especially if the relationship is deemed satisfactory between a state and an MCO like Centene. Beyond these contractually stipulated arrangements, the relationships between a state and its managed care plan providers can last much longer than one request for proposal cycle. For example, the length of Centene and its predecessor firms’ relationships with state Medicaid plans averages over 15 years, by our calculations.
Other End Markets: Individual Plans Face Enrollment and Margin Challenges as Subsidies Expire
We see positive characteristics in Centene’s other major business segments—commercial (primarily plans for the individual exchanges) and Medicare. Both businesses typically enjoy higher margins than the firm’s Medicaid business, which could help the company generate excess economic profits eventually. However, the risks surrounding the individual exchanges make the intermediate-term outlook murkier than we would like for a narrow-moat firm.
On the exchanges, Centene claims the top position in the US and aims to be the cost leader in the geographies it serves. Like other insurance markets, we think price remains a key determinant of market share, especially in this price-sensitive population that includes the recently unemployed. Centene also strives to maintain continuity of services for seasonal employees who often shift between Medicaid and the exchanges throughout the year, depending on their seasonal income level. Brand recognition in this population, along with a low-priced offering, has helped Centene build the leading market share on the individual exchanges. Given the cost advantage and intangible assets inherent in the individual exchange business, we believe Centene’s individual exchange business could eventually help it redig an economic moat, if it can regain profitability after expired federal subsidies threaten enrollment and mix in that population starting in 2026.
In Medicare, though, we do not believe Centene has dug an economic moat yet and may not for a long time. In the Medicare Advantage business, which was primarily acquired through the WellCare merger in early 2020, Centene remains a second-tier player, and the organization may remain constrained by weaker star ratings (a measure of plan quality) than many of its peers, which affects marketing to seniors and bonus payments. With lower bonus payments, Centene may have trouble expanding the breadth and depth of its extra benefit offerings, which can limit the attractiveness of its plans for end users relative to Centene’s peers. Also, with those lower star ratings, Centene may have less profit to share with its provider networks, which can influence incentives for that key constituent group. We think brand awareness may be lower than key peers in this niche too, where intangible assets make a difference for end users, who are typically the primary decision-makers for these plans. While we think Medicare may wind up being a good growth and margin opportunity for Centene, we think the company probably has a lot of digging to do in this business to reach moaty status.
Bull case
Centene represents a countercyclical investment opportunity in managed care, as it can benefit from economic downturns through increasing enrollment in its Medicaid and individual exchange products.
With a focus on government-sponsored programs, Centene could eventually benefit from potential US policy changes to reach universal affordable coverage in the long run.
With operating margins near breakeven levels, we see lots of potential to expand profits.
Bear case
Republicans are taking aim at Centene's Medicaid and individual exchange strongholds as avenues to reduce federal spending, which is cutting into the company's profit prospects.
Centene's near- and long-term earnings power appears more uncertain than usual, creating risks for investors.
The company's large debt position may need to be refinanced, and accessing the debt market is not guaranteed, especially if profits do not rise substantially.
By Julie Utterback, CFA
Quote time 2026-11-20 20:01:28 · For reference only, not investment advice and not tailored to your situation.
Centene discussion 0 comments